Clinical Trial Update: A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/2 trial evaluating intravenous brincidofovir in relapsed or refractory lymphoma, including extranodal NK/T-cell lymphoma (ENKL), is currently suspend…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma Nasal Type
• Lymphoma

Drugs mentioned

• Brincidofovir (brincidofovir)

Snippet

Sponsor: SymBio Pharmaceuticals | Conditions: Relapsed or Refractory Lymphoma Including ENKL | Phase 1, Phase 2 | Status: SUSPENDED